Tag: Arthritis: Rheumatoid
Study Compares Hospitalized Infection Risk for Biologics in RA
Risk of hospitalized infection increased with etanercept, infliximab, rituximab versus abatacept
Nonlinear Link for LDL, HDL With MACE Similar in RA, Non-RA
Nonlinear relationships seen in RA patients do not differ significantly from non-RA controls
Weekly Leflunomide Effective for Early Rheumatoid Arthritis
Similar benefits seen with weekly 50 mg dose versus daily 10 mg dose
Total Knee Arthroplasty Effective Option for Rheumatoid Arthritis
Procedure can 'turn back time' on the joints, at least temporarily
Weight Loss Predicts Mortality in Rheumatoid Arthritis
Highest risk seen with high annual weight loss rate, low BMI in previously obese
Arthritis Patients Want Info About Multiple Drug Options
Patients with inflammatory arthritis want to be informed about current, future treatment options
Rituximab Retreatment at Clinical Relapse Cost-Effective in RA
At least as cost-effective as more intensive regimen in patients with longstanding RA
Early Age of Menopause Linked to Seropositivity in RA
Increased odds of seropositivity in women with menopause <45 years versus ≥45 years
European League Against Rheumatism, June 10-13
The European League Against Rheumatism 2015 Annual European Congress of Rheumatology The annual meeting of the European League Against Rheumatism (EULAR) was held...
Most Part D Plans Cover at Least One Biologic DMARD
In most plans, patients required to pay coinsurance percentage, averaging 29.6 percent of drug costs
